Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours, vol. 1. IARC Press: Lyon, France, 2001, pp 291–302.

    Google Scholar 

  2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603–625.

    Article  CAS  Google Scholar 

  3. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014; 25: 1691–1700.

    Article  CAS  Google Scholar 

  4. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A . A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011; 86: 531–535.

    Article  CAS  Google Scholar 

  5. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotar K, Hermine O et al. Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood 2014; 124: 636.

    Google Scholar 

  6. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264–3274.

    Article  Google Scholar 

  7. Krauth MT, Bohm A, Agis H, Sonneck K, Samorapoompichit P, Florian S et al. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 2007; 35: 108–116.

    Article  CAS  Google Scholar 

  8. Valent P, Akin C, Escribano L, Födinger M, Hatmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435–453.

    Article  CAS  Google Scholar 

  9. van Der Velden VH, Te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204.

    Article  CAS  Google Scholar 

  10. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996; 149: 1493–1499.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149: 376–382.

    Article  CAS  Google Scholar 

  12. Jeong DK, Fauman K, Ross C, Akin C, Mody R . Successful treatment of systemic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC-based AML chemotherapy along with gemtuzumab. J Allergy Clin Immunol 2007; 119, (Suppl 1) S207 (abstract 814).

    Google Scholar 

  13. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635–641.

    Article  CAS  Google Scholar 

  14. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393–2401.

    Article  CAS  Google Scholar 

  15. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Fundación Mutua Madrileña (Madrid, Spain), Asociación Española de Enfermos de Mastocitosis (Madrid, Spain), Fundación Ramón Areces, Madrid, Spain (grant CIVP16A1806), Red Temática de Investigación Cooperativa en Cancer (RTICC) of the Instituto de Salud Carlos III, Ministry of Economy and Competitivity, Madrid, Spain (grant RD12/0036/0048, FEDER), Fundación Samuel Solorzano, Salamanca, Spain (grant FS/22-2014), and the Charles and Ann Johnson Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I Alvarez-Twose.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alvarez-Twose, I., Martínez-Barranco, P., Gotlib, J. et al. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. Leukemia 30, 1753–1756 (2016). https://doi.org/10.1038/leu.2016.30

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.30

This article is cited by

Search

Quick links